Veru Sees Unusually High Options Volume (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU) saw unusually large options trading activity on Monday. Investors bought 9,142 call options on the stock. This represents an increase of 206% compared to the average daily volume of 2,983 call options.

Insiders Place Their Bets

In other Veru news, Director Michael L. Rankowitz bought 95,279 shares of Veru stock in a transaction on Tuesday, February 18th. The stock was purchased at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the purchase, the director now directly owns 195,279 shares of the company’s stock, valued at $107,403.45. The trade was a 95.28 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 14.90% of the company’s stock.

Hedge Funds Weigh In On Veru

Large investors have recently modified their holdings of the company. PVG Asset Management Corp grew its holdings in Veru by 64.4% during the 4th quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company’s stock valued at $681,000 after buying an additional 410,340 shares in the last quarter. MPM Bioimpact LLC bought a new stake in shares of Veru during the 4th quarter valued at about $2,788,000. Cetera Investment Advisers boosted its position in shares of Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company’s stock valued at $62,000 after acquiring an additional 19,724 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Veru by 17.5% during the 4th quarter. Bank of America Corp DE now owns 217,792 shares of the company’s stock valued at $142,000 after acquiring an additional 32,447 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Veru by 35.2% during the 4th quarter. Jane Street Group LLC now owns 130,406 shares of the company’s stock valued at $85,000 after acquiring an additional 33,952 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Veru in a report on Thursday, January 2nd.

Veru Trading Up 3.6 %

Shares of NASDAQ:VERU traded up $0.02 on Monday, hitting $0.50. The company had a trading volume of 831,264 shares, compared to its average volume of 1,971,439. Veru has a 1-year low of $0.45 and a 1-year high of $1.92. The stock has a market cap of $73.48 million, a price-to-earnings ratio of -1.95 and a beta of -0.46. The stock has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.72.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. Sell-side analysts anticipate that Veru will post -0.22 earnings per share for the current fiscal year.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.